Actively Recruiting

Phase 3

Age: 50Years +

All Genders

ID07241390

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Orforglipron on Major Cardiovascular Events in Adults With Atherosclerotic Cardiovascular Disease andor Chronic Kidney Disease

Led by Eli Lilly and Company

Updated on 2026-06-04

7140

Participants Needed

568

Research Sites

N/A

Total Duration

On this page

AI-Summary

Brief Title

Who Can Participate

AI-Screening

Your Study Journey

Trial Site Locations

Research Team

How is the study designed?

Similar Trials

Frequently Asked Questions

AI-Summary

What This Trial Is About

This trial investigates how orforglipron affects cardiovascular outcomes in adults with established atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. The study focuses on measuring major cardiovascular events and kidney outcomes over about five years to better understand the drugs impact compared with placebo. Participants are randomly assigned to receive either orforglipron or a placebo,



both taken orally alongside their standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. The treatment period lasts for about five years, during which participants are closely monitored. During the study, participants will have regular assessments to track the time to the first major cardiovascular event, kidney function changes, and the onset of type 2 diabetes. These measurements will help evaluate the drugs effects over the study duration. Safety and health status will be monitored throughout participation, which lasts approximately five years in total.

CONDITIONS

Brief Title

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Who Can Participate

Age: 50Years +

All Genders

Eligibility Criteria

You may qualify if you...

Have established ath

📌 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of Orforglipron On Major Cardiovascular Events In Adults With Atherosclerotic Cardiovascular Disease Andor Chronic Kidney Disease (Bahía Blanca)
🏢 DecenTrialz
📍 Bahía Blanca